Comparing PLX And Celgegen Corporation
Ticker: (PLX)
Country & Exchange: United States; NYSE
Recommendation: HOLD
Ticker: (CELG)
Country & Exchange: United States; Nasdaq
Recommendation: BUY
Finance Information System
Professor Zhang
Research Project
Overview of Biotechnology Sector
This equity research project will be dedicated to valuing Protalix BioTherapeutics Inc.(PLX), and Celgene Corp. (CELG). Both companies compete in the Biotechnology sector, within the healthcare industry. Both PLX and CELG are publicly traded on the NYSE and Nasdaq, respectively. Before sharing my due diligence on each company, I will first explain and examine the industry and sentiment of the Biotechnology sector. The Biotechnology industry emerged in the 1970’s; as a result of the enhancement in heal care technology, which could provide synthetic ingredients with extraordinary benefits for the healthcare industry. These advanced …show more content…
Through my analysis of the FCF model, I have PLX valued at $5.52, nearly a dollar difference in its current price. I am not very optimistic of PLX due to its intense competition from companies like Vertex Pharmaceuticals, Celgene and Alexion Pharmaceuticals, who are more attractive investments are have a greater market share. PLX is also limited to only two products at this point, to which if one does not continue success it can prove further risk to the company. I feel that PLX is appropriately valued, and its current conditions are already reflected into its stock price. My future forecast for PLX is somewhat stable, to where the company will grow modestly over the long term and perhaps see reasonable profits based on their current situation. The company is extremely limited to capital as well as a diversity of products which make it difficult to invest in. Despite the company appearing to be very cheap, the equity seems to be somewhat stagnate in value, and future success of the company seems very
Country & Exchange: United States; NYSE
Recommendation: HOLD
Ticker: (CELG)
Country & Exchange: United States; Nasdaq
Recommendation: BUY
Finance Information System
Professor Zhang
Research Project
Overview of Biotechnology Sector
This equity research project will be dedicated to valuing Protalix BioTherapeutics Inc.(PLX), and Celgene Corp. (CELG). Both companies compete in the Biotechnology sector, within the healthcare industry. Both PLX and CELG are publicly traded on the NYSE and Nasdaq, respectively. Before sharing my due diligence on each company, I will first explain and examine the industry and sentiment of the Biotechnology sector. The Biotechnology industry emerged in the 1970’s; as a result of the enhancement in heal care technology, which could provide synthetic ingredients with extraordinary benefits for the healthcare industry. These advanced …show more content…
Through my analysis of the FCF model, I have PLX valued at $5.52, nearly a dollar difference in its current price. I am not very optimistic of PLX due to its intense competition from companies like Vertex Pharmaceuticals, Celgene and Alexion Pharmaceuticals, who are more attractive investments are have a greater market share. PLX is also limited to only two products at this point, to which if one does not continue success it can prove further risk to the company. I feel that PLX is appropriately valued, and its current conditions are already reflected into its stock price. My future forecast for PLX is somewhat stable, to where the company will grow modestly over the long term and perhaps see reasonable profits based on their current situation. The company is extremely limited to capital as well as a diversity of products which make it difficult to invest in. Despite the company appearing to be very cheap, the equity seems to be somewhat stagnate in value, and future success of the company seems very